WO2016154508A8 - In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping - Google Patents

In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping Download PDF

Info

Publication number
WO2016154508A8
WO2016154508A8 PCT/US2016/024146 US2016024146W WO2016154508A8 WO 2016154508 A8 WO2016154508 A8 WO 2016154508A8 US 2016024146 W US2016024146 W US 2016024146W WO 2016154508 A8 WO2016154508 A8 WO 2016154508A8
Authority
WO
WIPO (PCT)
Prior art keywords
her2
cells
patients
expansion
response
Prior art date
Application number
PCT/US2016/024146
Other languages
French (fr)
Other versions
WO2016154508A1 (en
Inventor
Brian J. Czerniecki
Lea LOWENFELD
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Priority to CN201680028189.2A priority Critical patent/CN108289910A/en
Priority to EP16769745.7A priority patent/EP3273975A4/en
Priority to JP2017550510A priority patent/JP2018510644A/en
Priority to CA2981033A priority patent/CA2981033A1/en
Publication of WO2016154508A1 publication Critical patent/WO2016154508A1/en
Publication of WO2016154508A8 publication Critical patent/WO2016154508A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

HER2+ invasive breast cancer (IBC) patients with residual disease following neoadjuvant chemotherapy have an anti-HER2 Type 1 T helper (Th1) cell immune deficit and a significant risk of recurrent disease. It has been shown that anti-HER2 CD4+ T-cell responses incrementally decrease along the breast cancer continuum - a robust response in healthy donors and patients with benign disease, a depressed response in patients with HER2+ ductal carcinoma in situ, and a nearly absent response in patients with HER2+ IBC. This invention relates to a method of creating a microenvironment for culture expansion of T cells. The expanded T cells can be used for a variety of therapeutic and research purposes.
PCT/US2016/024146 2015-03-26 2016-03-25 In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping WO2016154508A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201680028189.2A CN108289910A (en) 2015-03-26 2016-03-25 Artificial lymph node is for treating and the sensitization and amplification of the T cell of epitope mapping in vitro
EP16769745.7A EP3273975A4 (en) 2015-03-26 2016-03-25 In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping
JP2017550510A JP2018510644A (en) 2015-03-26 2016-03-25 In vitro artificial lymph nodes for sensitization and proliferation of T cells for therapy and epitope mapping
CA2981033A CA2981033A1 (en) 2015-03-26 2016-03-25 In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562138969P 2015-03-26 2015-03-26
US201562138684P 2015-03-26 2015-03-26
US62/138,684 2015-03-26
US62/138,969 2015-03-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017251792A Division AU2017251792A1 (en) 2015-03-26 2017-10-26 In Vitro Artificial Lymph Node for Sensitization and Expansion of T Cells for Therapy and Epitope Mapping

Publications (2)

Publication Number Publication Date
WO2016154508A1 WO2016154508A1 (en) 2016-09-29
WO2016154508A8 true WO2016154508A8 (en) 2018-03-15

Family

ID=56977770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/024146 WO2016154508A1 (en) 2015-03-26 2016-03-25 In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping

Country Status (5)

Country Link
EP (1) EP3273975A4 (en)
JP (1) JP2018510644A (en)
CN (1) CN108289910A (en)
CA (1) CA2981033A1 (en)
WO (1) WO2016154508A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986687A1 (en) * 2015-05-22 2016-12-01 Brian J. Czerniecki Manufacturing multi-dose injection ready dendritic cell vaccines
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035282A1 (en) * 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
WO2010027094A1 (en) * 2008-09-08 2010-03-11 独立行政法人理化学研究所 NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM
EP3854870A1 (en) * 2009-08-24 2021-07-28 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2011146473A1 (en) * 2010-05-17 2011-11-24 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
RS56339B1 (en) * 2010-09-20 2017-12-29 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
US8741642B2 (en) * 2010-10-22 2014-06-03 Virginia Commonwealth University Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects
JP2014511704A (en) * 2011-04-13 2014-05-19 イミュニカム・エイビイ Method for priming T cells

Also Published As

Publication number Publication date
JP2018510644A (en) 2018-04-19
EP3273975A4 (en) 2018-10-17
CN108289910A (en) 2018-07-17
WO2016154508A1 (en) 2016-09-29
EP3273975A1 (en) 2018-01-31
CA2981033A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
WO2016154508A8 (en) In vitro artificial lymph node for sensitization and expansion of t cells for therapy and epitope mapping
PH12017500484A1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
MX2016005866A (en) Personalized immunotherapy against several neuronal and brain tumors.
MX2016014711A (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml).
PH12018500864A1 (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
MX2018010167A (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers.
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2018005273A (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers.
MX2019011148A (en) Treatment methods.
WO2016026854A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2023006039A (en) Immune cells defective for suv39h1.
WO2014008206A3 (en) DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
EP3826663A4 (en) Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
WO2019070161A3 (en) Articles and methods directed to personalized therapy of cancer
PH12018501723A1 (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
MX2020011793A (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers.
PH12016502008A1 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml)
EA201992860A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN LUNG CANCER IMMUNOTHERAPY, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC), SMALL-CELL LUNG CANCER (MRL) AND OTHER
MX2019013161A (en) Personalized immunotherapy against several neuronal and brain tumors.
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
Faucher More support for breast-conserving therapy for early breast cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16769745

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2981033

Country of ref document: CA

Ref document number: 2017550510

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE